Literature DB >> 1455404

Decreased platelet membrane fluidity due to glycation or acetylation of membrane proteins.

P D Winocour1, C Watala, D W Perry, R L Kinlough-Rathbone.   

Abstract

Platelets from diabetic subjects and animals are hypersensitive to agonists in vitro. Membrane fluidity modulates cell function and previously we observed reduced membrane fluidity in platelets from diabetic patients associated with hypersensitivity to thrombin. We previously reported that decreased fluidity of isolated platelet membranes from diabetic patients is associated with increased glycation of platelet membrane proteins, but not with any change in the cholesterol to phospholipid molar ratio. We have now examined in vitro whether incubation of platelet membranes in a high glucose medium causes sufficient glycation to reduce membrane fluidity. Incubation of platelet membranes from control subjects in a high glucose (16.1 mM) medium for 10 days at 37 degrees C led to an increase in the extent of glycation of membrane proteins and a decrease in membrane fluidity (indicated by an increase in steady state fluorescence polarization); most of the changes occurred within the first 3 days of incubation. Incubation of platelet membranes with 5.4 mM glucose had less effect. In contrast, incubation of platelet membranes with the same concentrations of 1-0-methylglucose did not cause a change in either the extent of glycation of proteins or membrane fluidity. We also determined if acetylation by aspirin or acetyl chloride of the sites available for glycation on platelet membrane proteins leads to a similar reduction in membrane fluidity. Pretreatment of platelet membranes with aspirin or acetyl chloride diminished the extent of glycation that occurred when platelet membranes were subsequently incubated with glucose, but membrane fluidity was reduced even in the absence of glucose; subsequent incubation with glucose caused no further reduction in membrane fluidity.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1455404

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  25 in total

1.  Unusual effects of aspirin on ticlopidine induced thrombolysis.

Authors:  R J Gryglewski; W Uracz; J Swieş
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

Review 2.  Insights into Diabetic Kidney Disease Using Urinary Proteomics and Bioinformatics.

Authors:  Julie A D Van; James W Scholey; Ana Konvalinka
Journal:  J Am Soc Nephrol       Date:  2017-02-03       Impact factor: 10.121

3.  Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin.

Authors:  Cezary Watala; Justyna Pluta; Jacek Golanski; Marcin Rozalski; Malgorzata Czyz; Zygmunt Trojanowski; Józef Drzewoski
Journal:  J Mol Med (Berl)       Date:  2004-11-10       Impact factor: 4.599

4.  Advanced glycation end products induce a prothrombotic phenotype in mice via interaction with platelet CD36.

Authors:  Weifei Zhu; Wei Li; Roy L Silverstein
Journal:  Blood       Date:  2012-03-19       Impact factor: 22.113

Review 5.  Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions.

Authors:  Anetta Undas; Kathleen E Brummel-Ziedins; Kenneth G Mann
Journal:  Blood       Date:  2006-12-05       Impact factor: 22.113

Review 6.  Diabetes and antiplatelet therapy: from bench to bedside.

Authors:  Jose R Rivas Rios; Francesco Franchi; Fabiana Rollini; Dominick J Angiolillo
Journal:  Cardiovasc Diagn Ther       Date:  2018-10

7.  Anti-platelet drug resistance in the prediction of thromboembolic complications after neurointervention.

Authors:  Dal-Sung Ryu; Chang-Ki Hong; Yoo-Sik Sim; Chang-Hyun Kim; Jin-Young Jung; Jin-Yang Joo
Journal:  J Korean Neurosurg Soc       Date:  2010-10-30

8.  Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting.

Authors:  S Prabhakaran; K R Wells; V H Lee; C A Flaherty; D K Lopes
Journal:  AJNR Am J Neuroradiol       Date:  2007-11-07       Impact factor: 3.825

9.  Comparison of triple anti-platelet therapy (aspirin, clopidogrel, and cilostazol) and double anti-platelet therapy (aspirin and clopidogrel) on platelet aggregation in type 2 diabetic patients undergoing drug-eluting stent implantation.

Authors:  Tae-Hyun Yang; Doo Il Kim; Jong Yoon Kim; Il Hwan Kim; Ki-Hun Kim; Yang Chun Han; Woong Kim; Sang Hoon Seol; Seong Man Kim; Dae Kyeong Kim; Dong Soo Kim
Journal:  Korean Circ J       Date:  2009-11-30       Impact factor: 3.243

Review 10.  Platelet function profiles in patients with diabetes mellitus.

Authors:  Fabiana Rollini; Francesco Franchi; Ana Muñiz-Lozano; Dominick J Angiolillo
Journal:  J Cardiovasc Transl Res       Date:  2013-02-13       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.